USA-based Caladrius Biosciences (Nasdaq: CLBS) has acquired an exclusive worldwide license to data from a late stage CD34+ cell therapy program for the treatment of chronic myocardial ischemia targeting refractory angina.
The CD34+ cell therapy program was an asset gained through the Baxalta acquisition by Shire (LSE: SHP) in 2016, though the Ireland-incorporated drugmaker is offloading it as part of its efforts to out-license non-strategic assets to sharpen the company focus on rare diseases.
"We believe that the growing body of clinical data in support of CD34+ cell therapy as a treatment for refractory angina is very encouraging"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze